Back to Search Start Over

The dark side of lipid metabolism in prostate and renal carcinoma: novel insights into molecular diagnostic and biomarker discovery.

Authors :
di Meo NA
Lasorsa F
Rutigliano M
Milella M
Ferro M
Battaglia M
Ditonno P
Lucarelli G
Source :
Expert review of molecular diagnostics [Expert Rev Mol Diagn] 2023 Apr; Vol. 23 (4), pp. 297-313. Date of Electronic Publication: 2023 Mar 28.
Publication Year :
2023

Abstract

Introduction: Lipidomics focuses on the in-depth analysis of lipids, which are crucial macromolecules involved in a wide range of metabolic pathways. The increased intracellular accumulation of different classes of lipids in renal cell carcinoma (RCC) and prostate cancer (PCa) cells may be caused by elevated absorption or by increased de novo lipogenesis as a consequence of lipid metabolism reprogramming. The involvement of cholesterol metabolism in cancer's aberrant pathways has also been demonstrated.<br />Areas Covered: This review provides an update on the most important lipidomics studies and applications in RCC and PCa, with a particular focus on how knowledge of aberrant lipid pathways may be used to identify biomarkers and novel therapeutic targets. In addition, the application of this methodologies have led to novel cancer subtypes identification and patient's risk stratification. Tracking tumor progression using specific biofluid metabolite profiles offers a huge translational opportunity for urological malignancies.<br />Expert Opinion: Lipidomics is a promising branch of 'omics' approach and should include in next decade new standardized analysis methods and randomized clinical trials in order to reach the aim to use this high-throughput technique in patient-tailored therapy perspective.

Details

Language :
English
ISSN :
1744-8352
Volume :
23
Issue :
4
Database :
MEDLINE
Journal :
Expert review of molecular diagnostics
Publication Type :
Academic Journal
Accession number :
36960789
Full Text :
https://doi.org/10.1080/14737159.2023.2195553